PRESS RELEASE

2016 disclosure of AbbVie UK ‘Transfers of value’ to healthcare professionals and organisations

Maidenhead, UK, 30 June, 2017 – ‘Disclosure UK’, the central UK database for pharmaceutical industry transparency reporting, released its second full year of data on 30th June 2017. AbbVie is pleased to have made a full contribution with an increased proportion of doctors now providing consent for their financial transactions with AbbVie to be shared. We see this as a vote of confidence in how these important relationships are achieving a remarkable impact on patients and society.

Nearly two thirds of AbbVie Transfer of value spend in 2016 was for Research & Development demonstrating that AbbVie investment is driving improved skills and infrastructure of NHS. UK doctors are helping us develop the next generation of breakthrough treatments and we are investing in supporting their agenda too. The value of successful grant applications to AbbVie from Healthcare Organisations to support their projects more than doubled in 2016.

We hope that confidence in transparency reporting continues to grow and that more doctors provide full consent in years ahead. To see AbbVie’s full data go to the Association of the British Pharmaceutical Industry website at: http://www.abpi.org.uk/our-work/disclosure/Pages/disclosure.aspx

About AbbVie
AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.co.uk.

Media:
Matthew Worrall
AbbVie
Matthew.worrall@abbvie.com

###

Prepared June 2017
AXCOR170881